Jason R Wiles1, Barbara Isemann2, Tomoyuki Mizuno3, Meredith E Tabangin4, Laura P Ward5, Henry Akinbi5, Alexander A Vinks6. 1. Perinatal Institute, Division of Neonatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 2. Department of Pharmacy, University of Cincinnati Medical Center, Cincinnati, OH. 3. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 4. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 5. Perinatal Institute, Division of Neonatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH. 6. Division of Clinical Pharmacology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH; Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH. Electronic address: sander.vinks@cchmc.org.
Abstract
OBJECTIVE: To characterize the population pharmacokinetics of oral methadone in neonates requiring pharmacologic treatment of neonatal abstinence syndrome and to develop a pharmacokinetic (PK) model toward an evidence-based treatment protocol. STUDY DESIGN: Based on a methadone dosing protocol, serum concentrations of methadone and its metabolites were assessed by high performance liquid chromatography-tandem mass spectrometry from dried blood spots. Population PK analysis was performed to determine the volume of distribution and clearance of oral methadone. Methadone plasma concentration-time profiles were simulated from the deduced PK model to optimize the dosing regimen. RESULTS: There was substantial interindividual variability in methadone concentrations. Blood concentrations of methadone were best described by a 1-compartment model with first-order absorption. The population mean estimates (coefficient of variation percentage) for oral clearance and volume of distribution were 8.94 (103%) L/h/70 kg and 177 (133%) L/70 kg, respectively. Optimized dosing strategies were developed based on the simulated PK profiles. We suggest a starting dose of 0.1 mg/kg per dose every 6 hours for most patients requiring pharmacologic treatment of neonatal abstinence syndrome followed by an expedited weaning phase. CONCLUSIONS: The proposed dosing regimen may reduce the cumulative dose of opioid and shorten the length of hospitalization. Future studies should aim to validate the simulated dosing schemes with clinical data and expand our understanding of the between-patient PK variability. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01754324.
OBJECTIVE: To characterize the population pharmacokinetics of oral methadone in neonates requiring pharmacologic treatment of neonatal abstinence syndrome and to develop a pharmacokinetic (PK) model toward an evidence-based treatment protocol. STUDY DESIGN: Based on a methadone dosing protocol, serum concentrations of methadone and its metabolites were assessed by high performance liquid chromatography-tandem mass spectrometry from dried blood spots. Population PK analysis was performed to determine the volume of distribution and clearance of oral methadone. Methadone plasma concentration-time profiles were simulated from the deduced PK model to optimize the dosing regimen. RESULTS: There was substantial interindividual variability in methadone concentrations. Blood concentrations of methadone were best described by a 1-compartment model with first-order absorption. The population mean estimates (coefficient of variation percentage) for oral clearance and volume of distribution were 8.94 (103%) L/h/70 kg and 177 (133%) L/70 kg, respectively. Optimized dosing strategies were developed based on the simulated PK profiles. We suggest a starting dose of 0.1 mg/kg per dose every 6 hours for most patients requiring pharmacologic treatment of neonatal abstinence syndrome followed by an expedited weaning phase. CONCLUSIONS: The proposed dosing regimen may reduce the cumulative dose of opioid and shorten the length of hospitalization. Future studies should aim to validate the simulated dosing schemes with clinical data and expand our understanding of the between-patient PK variability. TRIAL REGISTRATION: ClinicalTrials.gov: NCT01754324.
Authors: Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard Journal: J Pharmacokinet Pharmacodyn Date: 2006-06-07 Impact factor: 2.745
Authors: Hendrée E Jones; Karol Kaltenbach; Sarah H Heil; Susan M Stine; Mara G Coyle; Amelia M Arria; Kevin E O'Grady; Peter Selby; Peter R Martin; Gabriele Fischer Journal: N Engl J Med Date: 2010-12-09 Impact factor: 91.245
Authors: Stephen W Patrick; Robert E Schumacher; Brian D Benneyworth; Elizabeth E Krans; Jennifer M McAllister; Matthew M Davis Journal: JAMA Date: 2012-04-30 Impact factor: 56.272
Authors: Claudia F Clavijo; Keith L Hoffman; James J Thomas; Brendan Carvalho; Larry F Chu; David R Drover; Gregory B Hammer; Uwe Christians; Jeffrey L Galinkin Journal: Anal Bioanal Chem Date: 2011-03-12 Impact factor: 4.142
Authors: Robert M Ward; David R Drover; Gregory B Hammer; Christopher J Stemland; Steve Kern; Martin Tristani-Firouzi; Ralph A Lugo; Kristin Satterfield; Brian J Anderson Journal: Paediatr Anaesth Date: 2014-03-26 Impact factor: 2.556
Authors: Alexander A Vinks; Nieko C Punt; Frank Menke; Eric Kirkendall; Dawn Butler; Thomas J Duggan; DonnaMaria E Cortezzo; Sam Kiger; Tom Dietrich; Paul Spencer; Rob Keefer; Kenneth D R Setchell; Junfang Zhao; Joshua C Euteneuer; Tomoyuki Mizuno; Kevin R Dufendach Journal: Clin Pharmacol Ther Date: 2019-12-11 Impact factor: 6.875
Authors: Jonathan M Davis; Jeffrey Shenberger; Norma Terrin; Janis L Breeze; Mark Hudak; Elisha M Wachman; Peter Marro; Erica L Oliveira; Karen Harvey-Wilkes; Adam Czynski; Barbara Engelhardt; Karen D'Apolito; Debra Bogen; Barry Lester Journal: JAMA Pediatr Date: 2018-08-01 Impact factor: 16.193
Authors: Tomoyuki Mizuno; Katja M Gist; Zhiqian Gao; Michael F Wempe; Jeffrey Alten; David S Cooper; Stuart L Goldstein; Alexander A Vinks Journal: Clin Pharmacokinet Date: 2019-06 Impact factor: 6.447
Authors: Brooks T McPhail; Chie Emoto; Tsuyoshi Fukuda; Dawn Butler; Jason R Wiles; Henry Akinbi; Alexander A Vinks Journal: J Clin Pharmacol Date: 2019-12-09 Impact factor: 3.126
Authors: Tomoyuki Mizuno; Brooks T McPhail; Suyog Kamatkar; Scott Wexelblatt; Laura Ward; Uwe Christians; Henry T Akinbi; Alexander A Vinks Journal: Clin Pharmacokinet Date: 2021-02 Impact factor: 6.447